Form 4 Filing for Allogene Therapeutics, Inc.

Vicki L. Sato, a director at Allogene Therapeutics, Inc., was granted 95,400 Restricted Stock Units (RSUs) on June 18, 2026. Each RSU represents a contingent right to receive one share of the Companys Common Stock. These RSUs will vest in two equal semi-annual installments over a one-year period from the grant date, contingent upon continued service. The transaction, reported on Form 4, indicates a direct ownership nature with a transaction code 'A' for acquisition. The underlying security is Common Stock, with 95,400 shares vesting in total. The filing also notes that the RSUs have a conversion or exercise price, though no specific value is provided.